Monoclonal antibody to a human T cell antigen and methods of preparing same

Patent 4364937 Issued on December 21, 1982. Estimated Expiration Date:

January 8, 2000. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Inventors

Assignee

Ortho Pharmaceutical Corporation

Application

No. 06/110510 filed on 01/08/1980

US Classes:

530/388.75, Binds T-lymphocytic cell or component or product thereof (e.g., T cell, thymocyte, T-lineage bone marrow cell, T-lymphoblastoid cell, T-lineage acute lymphoblastic leukemia cell, T-lymphocytic cell-surface antigen, etc.)424/154.1, T lymphocytic cell (e.g., T cell, thymocyte, etc.)435/70.21, Producing monoclonal antibody435/948, Using viruses or cell lines436/548, Monoclonal antibody514/21, Produced by or extracted from animal tissue530/806, ANTIGENIC PEPTIDES OR PROTEINS530/808, MATERIALS AND PRODUCTS RELATED TO GENETIC ENGINEERING OR HYBRID OR FUSED CELL TECHNOLOGY, E.G., HYBRIDOMA, MONOCLONAL PRODUCTS, ETC.530/809, Fused cells, e.g., hybridoma, etc.530/868INVOLVING AUTOIMMUNITY, ALLERGY, IMMEDIATE HYPERSENSITIVITY, DELAYED HYPERSENSITIVITY, IMMUNOSUPPRESSION, OR IMMUNOTOLERANCE

Examiners

Primary: Fagelson, Anna P.

Attorney, Agent or Firm

Dellenbaugh; Geoffrey G.

International Classes

C07K 16/18 (20060101)
C07K 16/28 (20060101)
A61K 38/00 (20060101)

Abstract

Hybrid cell line for production of monoclonal antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Other References

Kennett, SSIE Data Bank, Abstract of Grant, 5/77-4/79, Ab. No. 1 CA 189303
Herzenberg et al., SSIE Data Bank, Abstract of Grant, 9/77-7/79, Ab. No. 1 CA 468120
Williams, Cell, vol. 12, Nov. 1977, pp. 663-670, 672, 673
Reinherz et al., (1) Proc. Nat. Acd. Sci. USA vol. 76, Aug. 1979, pp. 4061-4065
Reinherz et al., (2) J. of Immunol. vol. 123, Sep. 1979, pp. 1312-1317
Kung, Science, vol. 206, 19 Oct. 1979, pp. 347-349
Melchers, (Ed. Lymph, Hybridomas, 2nd, Workshop on Functional Properties of Tumors of the Blymph, Spring-Verlag, Berlin/NY 1978, pp. IX-XVIII
Yelton et al., Supra, pp. 1-7
Trucco et al., Supra, pp. 66-69
Levy et al., Supra, pp. 164-169
Hammerling et al., Supra, pp. 100-106
Iverson et al., Supra, pp. 192-194
Simpson et al., Supra, pp. 195-202
Ruddle, Supra, pp. 203-211
Taniguchi et al., Supra, pp. 212-216
Osborne et al., Supra, pp. 217-220
Saravia et al., Supra, pp. 224-231
Barnstable et al., Cell, vol. 14, May 1978, pp. 9-20
Fox, C & E News, Jan. 1, 1979, pp. 15-17
White et al., J. Exptl. Med. vol. 148, 1 Sep. 1978, pp. 664-673
Herzenberg et al., from Weir (ED) Handbook of Exptl. Immunol, Blackwell, London 3rd Ed., 1978, pp. 25.1-25.7
Cosimi et al., Surgery, vol. 40, 1976, pp. 155-163
Lampson et al., J. Supramolecular Structure, vol. 6, 1977, pp. 441-448
Tracco, Nature, vol. 273, 22 Jun. 1978, pp. 666-668